



Please type a plus sign (+) inside this box ☒

PTO/SB/08B (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/607,521		
		Filing Date	06-26-2003		
		First Named Inventor	SCHÄFER		
		Group Art Unit	1614		
		Examiner Name	R. Henley		
Sheet	2	of	2	Attorney Docket Number	DEAV2002/0044 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AFKHAM F et al., Late long-term treatment with the ACE inhibitor ramipril and the vasopeptidase inhibitor AVE7688 improves endothelial function and increases survival in old SHR, Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 367, No. Supplement 1, March 2003, pp R71	
		GILBERT R E et al., Novel approaches to the treatment of progressive renal disease, Current Opinion in Pharmacology, Vol. 1, No. 2, April 2001, pp 183-189	
		HAHN A, Effekte einer chronischen Behandlung mit dem ACE-Inhibitor Ramipril, dem ACE/NEP-Inhibitor AVE 7688 sowie in Kombination mit dem B2-Rezeptor-Antagonisten HOE 140 in adulten diabetischen und nicht-diabetischen Ratten, Dissertation Tierärztliche Hochschule, 'Online! May 26, 2003, pp 1-175	
		SCHÄFER S. et al., Charakterisierung der hypertensiven Nephropathy in spontan hypertensiven Ratten: Effektive Therapie durch den ACE-Hemmer Ramipril und den Vasopeptidase-Hemmer AVE 7688, Frühjahrstagung 2003 Der Deutschen Gesellschaft Für Kardiologie - Herz- Und Kreislaufforschung, Mannheim, April 24-26, 2003,	
		WECKLER N, Effekte einer chronischen Behandlung mit dem ACE-NEP-Inhibitor AVE 7688 und Ramipril auf die endotheliale Dysfunktion am Modell des atherogen gefütterten Kaninchens, Dissertation Justus-Liebig-Universität Giessen, 'Online! November 22, 2002, pp 1-110	

Examiner Signature		Date Considered	1/12/2005
-----------------------	--	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.